昭衍新药(06127)于今日早盘表现强劲,早盘较高时一度涨逾20%,截至发稿时报10.24港元/股,较上一交易日收盘价涨幅高达19.36%。引发该股价大涨的主要原因是公司发布了关于参与服务贸易创新发展引导基金二期的相关公告。
根据公告内容,公司作为生物医药领域代表性服务贸易企业,拟参与由财政部、商务部与招商局资本共同发起设立的服务贸易创新发展引导基金二期。该基金由招商局资本担任管理人,公司或其指定子公司作为有限合伙人将认缴出资不超过1亿元人民币。
此举被视为昭衍新药从战略层面在夯实产业基础、布局医疗健康产业方面的积极尝试。市场预期公司借助专业投资机构的优势,将提升盈利能力、实现新的利润增长点,为公司持续发展注入新动力。因此,公司股价在此利好消息的刺激下出现大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.